respiratory-antispasmodic
Lobelia inflata L.
The Small Sharp Corrective
Crystalis is a reference resource for herbal, crystal, and somatic practice.
This library is designed to help readers orient, compare, and research. It is not a substitute for medical care or practitioner judgment.
Botanical / meta
Slender annual or biennial in the bellflower family, worked from the aerial parts and seed. Lobelia inflata carries a sharp, acrid alkaloid profile and a correspondingly forceful reputation in historical practice. It is not a casual herb and belongs to precise low-dose work.
Lobelia inflata L. (Campanulaceae) is a herbaceous annual native to eastern North America, historically referred to as Indian Tobacco or Pukeweed. The plant produces a complex alkaloid profile dominated by lobeline (2-[6-(2-hydroxy-2-phenylethyl)-1-methylpiperidin-2-yl]-1-phenylethanone), which constitutes approximately 0.3-0.4% of dried aerial herb weight. Additional piperidine alkaloids include lobelanine, lobelanidine, norlobelanine, and isolobinine. The total alkaloid content of the aerial parts ranges from 0.2% to 0.6% depending on harvest stage, with peak concentrations occurring during the fruiting phase. Lobeline functions pharmacologically as a mixed agonist-antagonist at nicotinic acetylcholine receptors (nAChRs). It binds with high affinity to both heteromeric (alpha4-beta2) and homomeric (alpha7) nAChR subtypes, with Ki values in the low nanomolar range at alpha4-beta2 receptors. Critically, lobeline does not produce the reinforcing effects typical of nicotine: it does not increase locomotion, does not generalize to a nicotine discriminative stimulus, and does not produce conditioned place preference. Benwell & Balfour (1998) demonstrated that lobeline acts as a short-acting antagonist at nicotinic receptors mediating mesolimbic dopamine activity, abolishing nicotine-induced dopamine responses in the nucleus accumbens at doses of 4.0-10.0 mg/kg i.p. Beyond nAChR interaction, lobeline potently inhibits vesicular monoamine transporter-2 (VMAT2) function, blocking dopamine uptake and methamphetamine-evoked dopamine release from striatal vesicles. It also inhibits dopamine transporter (DAT) function and acts as a mu-opioid receptor antagonist. Lobelia was listed in the United States Pharmacopeia from 1820 to 1936 as an expectorant and respiratory stimulant. Samuel Thomson, the 19th-century herbalist, considered it the most important plant in his materia medica, employing it as an emetic and antispasmodic. The Eclectic physicians used lobelia tincture extensively for bronchial asthma, whooping cough, and as an adjunctive agent in nicotine withdrawal. Contemporary research has focused on lobeline analogs (lobelane, GZ-793A) as pharmacological tools for methamphetamine addiction, exploiting the VMAT2 interaction. Lobeline has been evaluated in human clinical trials for methamphetamine addiction and found to be safe in addicted populations (Jones, 2007).
Lobelia acts through intensity. Lobeline and related alkaloids change respiratory and neuromuscular tone quickly, so the herb sits in spasm, breath, and emetic histories all at once. It demands dosage discipline and works best in skilled formulation rather than enthusiastic self-experiment.
The Small Sharp Corrective
Lobelia is usually reached for when the body is spasmodic, tight, or respiratory effort feels badly coordinated. It belongs first to the low-dose corrective lane, never to broad self-directed experimentation.
The practical read
Lobelia only sounds wise when the page remembers that dosage is part of the plant's identity. This is not a generous herb. It is potent, potentially nauseating, and useful precisely because it is narrow. Lobelia belongs to older respiratory and spasm language, but modern authority depends on restraint. The plant's place in the canon is as a specialist, not as a wellness herb. That difference should stay visible from the first sentence forward.
Lobelia inflata L. (Campanulaceae) is a herbaceous annual native to eastern North America, historically referred to as Indian Tobacco or Pukeweed. The plant produces a complex alkaloid profile dominated by lobeline (2-[6-(2-hydroxy-2-phenylethyl)-1-methylpiperidin-2-yl]-1-phenylethanone), which constitutes approximately 0.3-0.4% of dried aerial herb weight. Additional piperidine alkaloids include lobelanine, lobelanidine, norlobelanine, and isolobinine. The total alkaloid content of the aerial parts ranges from 0.2% to 0.6% depending on harvest stage, with peak concentrations occurring during the fruiting phase. Lobeline functions pharmacologically as a mixed agonist-antagonist at nicotinic acetylcholine receptors (nAChRs). It binds with high affinity to both heteromeric (alpha4-beta2) and homomeric (alpha7) nAChR subtypes, with Ki values in the low nanomolar range at alpha4-beta2 receptors. Critically, lobeline does not produce the reinforcing effects typical of nicotine: it does not increase locomotion, does not generalize to a nicotine discriminative stimulus, and does not produce conditioned place preference. Benwell & Balfour (1998) demonstrated that lobeline acts as a short-acting antagonist at nicotinic receptors mediating mesolimbic dopamine activity, abolishing nicotine-induced dopamine responses in the nucleus accumbens at doses of 4.0-10.0 mg/kg i.p. Beyond nAChR interaction, lobeline potently inhibits vesicular monoamine transporter-2 (VMAT2) function, blocking dopamine uptake and methamphetamine-evoked dopamine release from striatal vesicles. It also inhibits dopamine transporter (DAT) function and acts as a mu-opioid receptor antagonist. Lobelia was listed in the United States Pharmacopeia from 1820 to 1936 as an expectorant and respiratory stimulant. Samuel Thomson, the 19th-century herbalist, considered it the most important plant in his materia medica, employing it as an emetic and antispasmodic. The Eclectic physicians used lobelia tincture extensively for bronchial asthma, whooping cough, and as an adjunctive agent in nicotine withdrawal. Contemporary research has focused on lobeline analogs (lobelane, GZ-793A) as pharmacological tools for methamphetamine addiction, exploiting the VMAT2 interaction. Lobeline has been evaluated in human clinical trials for methamphetamine addiction and found to be safe in addicted populations (Jones, 2007).
Lobelia is usually reached for when the body is spasmodic, tight, or respiratory effort feels badly coordinated. It belongs first to the low-dose corrective lane, never to broad self-directed experimentation.
Route panel
Evidence and safety may differ by preparation. Essential oil, tea, tincture, extract, infused oil, and topical use are not interchangeable.
Preparations
A carefully dosed lobeline-containing tincture for acute bronchospasm and tight breathing.
2 min (prep) + sourcing
Narrow therapeutic index: emetic doses are close to therapeutic doses. Nausea and vomiting occur in 30-50% of users at higher doses. Contraindicated in pregnancy, cardiac arrhythmias, hypertension, and seizure disorders. Do not combine with nicotine replacement therapy.
A topical application delivering lobeline through the skin to ease respiratory tightness without oral-dose risks.
20 min
Topical route avoids the nausea risk of oral dosing. Lobeline acts on nicotinic acetylcholine receptors. Contraindicated in pregnancy. Not for children. If skin irritation occurs, discontinue immediately.
Comparison
Lobelia sometimes appears beside mullein or osha in lung formulas, but it does different work and demands a tighter hand.
Choose lobelia only when the protocol truly calls for a small corrective herb. Do not write it as a casual tea.
Quality
Fresh herb should smell green and bitter, not rotten or lax.
Dried lobelia should be clearly identified and carefully sourced. This is not a plant for anonymous bulk material.
Lobelia is not an oil herb. Keep the route language disciplined.
Lobelia prefers moisture and respectful handling. The more important cultivation note is that not every herb belongs in beginner hands.
Companion
With obsidian, lobelia reads as a small hard correction, not a soft ally.
Lobelia and blue kyanite share a polyvagal architecture rooted in ventral vagal activation under respiratory distress. When bronchospasm triggers sympathetic overdrive; the panic of not being able to breathe; lobeline intervenes at the receptor level, antagonizing the excessive cholinergic signaling that drives smooth muscle contraction. Blue kyanite, in energetic practice, is placed at the throat during breathwork to facilitate the transition from sympathetic constriction to ventral vagal openness. The pairing addresses the same territory: the moment between constriction and release. In practical application, holding blue kyanite during lobelia-supported breathing exercises creates a dual-channel intervention. The alkaloid acts pharmacologically on nAChR-mediated bronchial tone while the crystal serves as a proprioceptive anchor for the throat and upper chest. For practitioners working with clients who hold tension in the respiratory apparatus; singers, public speakers, individuals with anxiety-driven shallow breathing; this pairing offers a somatic reset that honors both the biochemical and the energetic dimensions of breath.
Crystal side
The deeper layer
Clinical and compound notes are included as a research layer, not as treatment instructions.
Contraindications: Lobelia has a narrow therapeutic index. Emetic doses are close to therapeutic doses. Contraindicated in pregnancy (uterine stimulant properties), lactation, and in children. Individuals with cardiac arrhythmias, hypertension, or seizure disorders should avoid use. Concurrent use with nicotine replacement therapy (patches, gums) or varenicline may produce additive cholinergic effects. Drug Interactions: Potentiates effects of other cholinergic agents. May interact with MAO inhibitors due to effects on monoamine transport. Caution with antihypertensive medications (additive hypotension at high doses). Pregnancy/Lactation: Contraindicated. Category X equivalent — documented uterine stimulant effects. Hepatotoxicity Risk: Low at therapeutic doses. No documented hepatotoxicity. Dosage Ranges: Tincture (1:5, 60% ethanol): 0.5-1.0 mL three times daily. Dried herb: 200-600 mg daily. Standardized extract: lobeline content typically 1-2 mg per dose. Emetic threshold begins around 1.0 g dried herb. Adverse Reactions: Nausea and vomiting are the most common adverse effects, occurring in approximately 30-50% of users at higher doses. Other effects include diaphoresis, tachycardia followed by bradycardia, tremor, dizziness, and respiratory depression at toxic doses. LD50 in mice: approximately 50 mg/kg lobeline i.p.
Lore & history
Cultural notes are presented as tradition and historical context, attributed to where they come from.
The Penobscot people of present-day Maine smoked dried Lobelia leaves as a treatment for asthma and respiratory congestion. The plant was known as 'Indian tobacco' and used carefully in small quantities due to its potent emetic properties.
Cherokee healers administered Lobelia root preparations as an expectorant to clear congested lungs. Small doses were chewed or brewed into tea for coughs, while larger doses served as an emetic for ceremonial purification.
Samuel Thomson, founder of Thomsonian herbalism, made Lobelia inflata the cornerstone of his healing system. He used it as a primary emetic to 'cleanse the stomach' and restore bodily heat, sparking both a popular movement and fierce controversy with conventional physicians.
Eclectic physicians in the United States adopted Lobelia as a key antispasmodic remedy, prescribing tinctures in small doses for bronchial spasm, croup, and whooping cough. John King's 'American Dispensatory' detailed its use as a smooth-muscle relaxant.
Iroquois healers prepared Lobelia as a gargle and throat wash for treating sore throats and oral infections. The plant was also applied externally as a poultice for muscle stiffness and body aches after strenuous labor.
Questions
Lobelia has a narrow therapeutic index, meaning emetic doses are close to therapeutic doses. Lobeline, its primary alkaloid, is a mixed agonist-antagonist at nicotinic acetylcholine receptors with an LD50 of approximately 50 mg/kg in mice. It is contraindicated in pregnancy (uterine stimulant), cardiac arrhythmias, seizure disorders, and must never be combined with nicotine replacement therapy due to additive cholinergic toxicity.
Tincture (1:5, 60% ethanol) is typically dosed at 0.5-1.0 mL three times daily, or 200-600 mg dried herb daily. Standardized extracts provide 1-2 mg lobeline per dose. The emetic threshold begins around 1.0 g dried herb, so dosing precision matters. Start at the lowest effective amount and titrate cautiously under practitioner guidance.
Fresh lobelia herb should smell green and distinctly bitter. Dried material should be clearly identified as Lobelia inflata with harvest stage noted, as peak alkaloid content (0.2-0.6%) occurs during the fruiting phase. This is not a plant for anonymous bulk sourcing; verified botanical identity is non-negotiable given the narrow therapeutic index.
Lobeline binds alpha4-beta2 nicotinic receptors with high affinity but does not produce nicotine's reinforcing effects: no increased locomotion, no conditioned place preference, and no mesolimbic dopamine surge. It functions as a short-acting antagonist at reward-pathway receptors. Nicotine replacement provides agonist substitution, while lobeline blocks the reward signal without creating dependence.
Store lobelia tinctures in amber glass away from heat and light; the 60% ethanol base preserves alkaloid stability for 3-5 years. Dried herb should be kept in airtight containers in cool, dark conditions and used within 1-2 years, as piperidine alkaloid content degrades with oxidation and moisture exposure.
Sources & Citations
Peer-reviewed sources for the pharmacological and clinical claims on this page. Crystalis herb entries describe tradition and current research; they are reference, not medical advice.
SCI
SCI
Resource framing
Crystalis is a reference resource for herbal, crystal, and somatic practice.
This library is designed to help readers orient, compare, and research. It is not a substitute for medical care or practitioner judgment.
Clinical and compound notes are included as a research layer, not as treatment instructions.
Evidence and safety may differ by preparation. Essential oil, tea, tincture, extract, infused oil, and topical use are not interchangeable.